Experimental shot takes on deadly brain tumor
NCT ID NCT07497373
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single injection of JL15003 in 17 adults whose glioblastoma brain cancer had returned after standard treatments. The main goal was to check safety and find the best dose, while also looking at whether the virus in the injection spreads in the body and if the tumor shrinks. Participants were followed for 57 days, with long-term survival tracked for up to 15 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA MULTIFORME(GBM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tsinghua Changgung Hospital
Beijing, China
-
Huashan Hospital, Shanghai Medical College, Fudan University
Shanghai, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.